Lung Cancer—Non-Small Cell Metastatic
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
This study demostrates with 1t-line NIVO + IPI + chemotherapy after a 2 years’ minimum follow-up a durable survival and benefit vs chemotherapy in patients with advanced NSCLC; there were no new safety signals. CTI: NCT03215706
Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.
Oladimeji Akinboro, Jonathon Joseph Vallejo, Pallavi Shruti Mishra-Kalyani, et al.
In most subgroups of patients with advanced NSCLC with PD-L1 score, 1-49% chemo-IO may improve efficacy outcomes versus IO alone. Patients 75 and over across therapeutic options experienced similar outcomes.